Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.
Enhanced patient-specific intestine-on-a-chip model for disease modeling and drug discovery
This article describes advances in OrganoPlate® intestine-on-a-chip models—highlighting microfluidic platforms for high-throughput IBD research and new 14-day iPSC-derived gut tubules for personalized inflammation studies.